Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has announced the selection of Linical, a global contract research organization, to support its U.S. Food and Drug Administration-cleared Phase 1/2 clinical trial of Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer (TNBC). The filing details that Telomir has executed a Master Services Agreement and a clinical trial Work Order with Linical to establish the operational framework for the study.
Linical brings over two decades of experience in oncology clinical development, with approximately half of its oncology experience concentrated in early-phase studies. The CRO’s capabilities span Phase 1 through Phase 4 clinical development, including clinical trial startup, investigator-site coordination, patient recruitment, clinical monitoring, project management, biometrics, and regulatory support.
The clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of Telomir-Zn as a monotherapy. Telomir-Zn is an investigational oral epigenetic therapy designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor suppressor genes. The company is targeting clinical initiation for the first quarter of 2027.
In a statement regarding the partnership, Erez Aminov, Chairman and Chief Executive Officer of Telomir Pharmaceuticals, noted that the selection of Linical follows the FDA clearance of the company’s Investigational New Drug (IND) application and represents a key operational milestone.